Connect Biopharma Holdings Limited (NASDAQ:CNTB – Free Report) – Investment analysts at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for shares of Connect Biopharma in a note issued to investors on Sunday, April 6th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.83) per share for the year, down from their prior forecast of ($0.65). The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. Leerink Partnrs also issued estimates for Connect Biopharma’s FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at ($0.55) EPS and FY2029 earnings at ($0.26) EPS.
Separately, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Connect Biopharma in a research note on Monday, March 31st.
Connect Biopharma Trading Down 2.5 %
Shares of CNTB stock opened at $0.64 on Wednesday. Connect Biopharma has a 1 year low of $0.51 and a 1 year high of $2.08. The stock has a fifty day moving average of $0.81 and a two-hundred day moving average of $1.02.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in CNTB. Catalina Capital Group LLC acquired a new stake in Connect Biopharma in the fourth quarter worth approximately $66,000. Callan Capital LLC lifted its holdings in shares of Connect Biopharma by 91.3% in the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock valued at $110,000 after buying an additional 38,177 shares during the period. Finally, Choreo LLC acquired a new stake in shares of Connect Biopharma in the fourth quarter valued at $204,000. 58.72% of the stock is currently owned by institutional investors.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Read More
- Five stocks we like better than Connect Biopharma
- What Are Dividend Contenders? Investing in Dividend Contenders
- Joby Aviation: Operational Momentum vs. Market Sentiment
- Earnings Per Share Calculator: How to Calculate EPS
- Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline
- The Significance of Brokerage Rankings in Stock Selection
- Carvana: Can Turnaround Strength Outdrive Market Headwinds?
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
